Global Neurological Biomarkers Market Size, Trends, and Growth Opportunity, By Product Type (Imaging Biomarker, Genomics Biomarker, Proteomics Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Huntington's Disease, Alzheimer's Disease, Depression, Parkinson's Disease, Schizophrenia, Multiple Sclerosis), Imaging Techniques (Conventional Structural MRI, Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Testing, Sample Preparation, Biomarker Validation, and Assay Development), End- User (Pharmaceutical and Biotechnology Companies, Research Organizations, Clinical Diagnostics) By Region and forecast till 2030.
Global Neurological Biomarkers Market
The global Neurological Biomarkers Market was valued at USD 6.94 Billion in 2022 and is slated to reach USD 21.52 Billion by 2030 at a CAGR of 6.27 % from 2023-2030.
The biomarkers considered to be criteria for assessing and computing a method or symptom for gaining a pharmacological response to a specific treatment are neurological ones. They're frequently used to diagnose a variety of illnesses, including Parkinson's, autism, and depression. Imaging, genetics, proteomics, and metabolomics are the most typical categories of neurological biomarkers.
Market Drivers
Neurological illnesses are now more treatable thanks to biomarker signatures. Faster drug development, noninvasive testing, and early diagnosis were the outcomes of this. Digital biomarkers also give a lot of pharmaceutical businesses further data to make decisions about clinical trials. The National Institute of Neurological Disorders and Stroke funds researchers doing studies related to biomarker discovery, analytical validation, and clinical validation through development grants and cooperative agreements. This promotes market expansion. Personalized medicine is rapidly progressing in the domain of biomarker studies in neurodegenerative illness. Numerous compounds have been examined and linked to numerous neurodegenerative diseases. The biopharmaceutical sector has been impacted by changes in precision medicine. There will be a significant change that affect a variety of stakeholders, including biopharma companies and diagnostics businesses with a range of operations, including R&D and business operations. expected to have a favorable impact on the market expansion.
Market Restraints
The ability of the biomarkers to identify diseases varies. As a result, evaluating biomarkers takes time. As a result, the validation procedure becomes time- and money-consuming. With a few exceptions, the procedure and schedule for creating and validating biomarkers are thus identical across different types of biomarkers since different types of biomarkers usually go through the same stages of the creation and validation processes. This constraint prevents market growth.
Impact of COVID-19
Additionally, the epidemic has hampered efforts to create new neurological biomarkers and their investigation. Due to travel limitations and social distancing policies, clinical experiments have been postponed or stopped. New biomarkers and treatments are taking longer to develop as a result. However, the need for neurological biomarkers that are used in COVID-19 research has grown considerably. To track the progression of the illness and forecast results, biomarkers including cytokines and neurofilament light chain have been employed. New biomarker research for COVID-19 and other viral diseases is now receiving more attention as a result of this.
Recent Developments
Johnson & Johnson Services, Inc. and Enigma Biomedical Group engaged in a strategic partnership in 2020 to evaluate two novel neuroimaging biomarkers—JNJ-64413739 and JNJ-64511070—for a better understanding of Alzheimer's disease and other dementias.
Market Segmentation
Global Neurological Biomarkers Market is segmented By Product Type, Indication, Imaging Techniques, Services, End- User. By Product Types such as Imaging biomarkers, Genomics biomarkers, Proteomics biomarkers, Metabolomics biomarkers, and Others. By Indications such as Spinal Muscular Atrophy, Huntington's Disease, Alzheimer's Disease, Depression, Parkinson's Disease, Schizophrenia, and Multiple Sclerosis. By Imaging Techniques such as Conventional Structural MRI, Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Functional Magnetic Resonance Imaging, and Positron Emission Tomography. By Services such as Testing, Sample Preparation, Biomarker Validation, and Assay Development. By End- User such as Pharmaceutical and Biotechnology Companies, Research Organizations, and Clinical Diagnostics.
Regional Analysis
The global Neurological Biomarkers Market is segmented into five regions Europe, Asia-Pacific, Americas and the Middle East & Africa. Due to rising healthcare costs and the enormous economic success of neurological diagnostics in the United States, North America dominates the market for neurological biomarkers. Additionally, it is projected that the rising number of product releases would have a beneficial effect on the regional market, as will the rising demand for biomarkers. Because of the region's improved healthcare infrastructure and rising disposable income, Asia-Pacific is predicted to experience significant growth. Additionally, a rise in clinical studies conducted in developing nations like China and India fuels industry expansion.
Key Players
This report includes a list of numerous Key Players, namely bioMérieux Inc (U.S.), Thermo Fisher Scientific (U.S.), QIAGEN (Netherlands), McKesson Corporation (U.S), Advanced Brain Monitoring, Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), BGI (China), Quanterix (U.S.), Neurosteer Inc. (U.S.), R1 RCM Inc., (U.S).
Market Taxonomy
By Product Type
• Genomics Biomarker
• Proteomics Biomarker
• Imaging Biomarker
• Metabolomics Biomarker
• Others
By Indication
• Spinal Muscular Atrophy
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Alzheimer's Disease
• Depression
• Multiple Sclerosis
By Imaging Techniques
• Transcranial Magnetic Stimulation
• Diffusion Tensor Imaging
• Conventional Structural MRI
• Functional Magnetic Resonance Imaging
• Positron Emission Tomography
By Services
• Sample Preparation
• Assay Development
• Biomarker Validation and Testing
By End User
• Clinical Diagnostics
• Pharmaceutical And Biotechnology Companies
• Research Organizations
By Region
• North America Latin America
• Europe
• Asia Pacific
• Middle East & Africa.
Global Neurological Biomarkers Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Neurological Biomarkers Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Neurological Biomarkers Market, By Indication
5.1 Y-o-Y Growth Comparison, By Indication
5.2 Global Neurological Biomarkers Market Share Analysis, By Indication
5.3 Global Neurological Biomarkers Market Size and Forecast, By Indication
5.3.1 Spinal Muscular Atrophy
5.3.2 Parkinson's Disease
5.3.3 Schizophrenia
5.3.4 Huntington's Disease
5.3.5 Alzheimer's Disease
5.3.6 Depression
5.3.7 Multiple Sclerosis
6 Global Neurological Biomarkers Market, By Product Type
6.1 Y-o-Y Growth Comparison, By Product Type
6.2 Global Neurological Biomarkers Market Share Analysis, By Product Type
6.3 Global Neurological Biomarkers Market Size and Forecast, By Product Type
6.3.1 Genomics Biomarker
6.3.2 Proteomics Biomarker
6.3.3 Imaging Biomarker
6.3.4 Metabolomics Biomarker
6.3.5 Others
7 Global Neurological Biomarkers Market, By Imaging Techniques
7.1 Y-o-Y Growth Comparison, By Imaging Techniques
7.2 Global Neurological Biomarkers Market Share Analysis, By Imaging Techniques
7.3 Global Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
7.3.1 Transcranial Magnetic Stimulation
7.3.2 Diffusion Tensor Imaging
7.3.3 Conventional Structural MRI
7.3.4 Functional Magnetic Resonance Imaging
7.3.5 Positron Emission Tomography
8 Global Neurological Biomarkers Market, By Services
8.1 Y-o-Y Growth Comparison, By Services
8.2 Global Neurological Biomarkers Market Share Analysis, By Services
8.3 Global Neurological Biomarkers Market Size and Forecast, By Services
8.3.1 Sample Preparation
8.3.2 Assay Development
8.3.3 Biomarker Validation and Testing
9 Global Neurological Biomarkers Market, By End User
9.1 Y-o-Y Growth Comparison, By End User
9.2 Global Neurological Biomarkers Market Share Analysis, By End User
9.3 Global Neurological Biomarkers Market Size and Forecast, By End User
9.3.1 Clinical Diagnostics
9.3.2 Pharmaceutical And Biotechnology Companies
9.3.3 Research Organizations
10 Global Neurological Biomarkers Market, By Region
10.1 Global Neurological Biomarkers Market Share Analysis, By Region
10.2 Global Neurological Biomarkers Market Share Analysis, By Region
10.3 Global Neurological Biomarkers Market Size and Forecast, By Region
11 North America Neurological Biomarkers Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Neurological Biomarkers Market Share Analysis, By Indication
11.3 North America Neurological Biomarkers Market Size and Forecast, By Product Type
11.4 North America Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
11.5 North America Neurological Biomarkers Market Size and Forecast, By Services
11.6 North America Neurological Biomarkers Market Size and Forecast, By End User
11.7 North America Neurological Biomarkers Market Size and Forecast, By Country
11.7.1 U.S.
11.7.2 Canada
11.7.3 Mexico
12 Europe Neurological Biomarkers Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Neurological Biomarkers Market Share Analysis, By Indication
12.3 Europe Neurological Biomarkers Market Size and Forecast, By Product Type
12.4 Europe Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
12.5 Europe Neurological Biomarkers Market Size and Forecast, By Services
12.6 Europe Neurological Biomarkers Market Size and Forecast, By End User
12.7 Europe Neurological Biomarkers Market Size and Forecast, By Country
12.7.1 Germany
12.7.2 France
12.7.3 UK
12.7.4. Rest of Europe
13 Asia Pacific Neurological Biomarkers Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Neurological Biomarkers Market Share Analysis, By Indication
13.3 Asia Pacific Neurological Biomarkers Market Size and Forecast, By Product Type
13.4 Asia Pacific Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
13.5 Asia Pacific Neurological Biomarkers Market Size and Forecast, By Services
13.6 Asia Pacific Neurological Biomarkers Market Size and Forecast, By End User
13.7 Asia Pacific Neurological Biomarkers Market Size and Forecast, By Country
13.7.1 China
13.7.2 Japan
13.7.3 India
13.7.4. Rest of Asia Pacific
14 Latin America Neurological Biomarkers Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Neurological Biomarkers Market Share Analysis, By Indication
14.3 Latin America Neurological Biomarkers Market Size and Forecast, By Product Type
14.4 Latin America Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
14.5 Latin America Neurological Biomarkers Market Size and Forecast, By Indication of Rider
14.6 Latin America Neurological Biomarkers Market Size and Forecast, By End User
14.7 Latin America Neurological Biomarkers Market Size and Forecast, Country
14.7.1. Brazil
14.7.2.Rest of Latin America
15 Middle East Neurological Biomarkers Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Neurological Biomarkers Market Share Analysis, By Indication
15.3 Middle East Neurological Biomarkers Market Size and Forecast, By Product Type
15.4 Middle East Neurological Biomarkers Market Size and Forecast, By Imaging Techniques
15.5 Middle East Neurological Biomarkers Market Size and Forecast, By Services
15.6 Middle East Neurological Biomarkers Market Size and Forecast, By End User
15.7 Middle East Neurological Biomarkers Market Size and Forecast, By Country
15.7.1. Saudi Arabia
15.7.2. UAE
15.7.3. Egypt
15.7.4. Kuwait
15.7.5. South Africa
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 Thermo Fisher Scientific (U.S.)
17.1.1 Overview
17.1.2 Types
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2. QIAGEN (Netherlands)
17.2.1 Overview
17.2.2 Types
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3. Advanced Brain Monitoring, Inc (U.S.)
17.3.1 Overview
17.3.2 Types
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Bio-Rad Laboratories, Inc. (U.S.)
17.4.1 Overview
17.4.2 Types
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 Agilent Technologies, Inc. (U.S.)
17.5.1 Overview
17.5.2 Types
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 F. Hoffmann-La Roche Ltd. (Switzerland)
17.6.1 Overview
17.6.2 Types
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 BGI (China)
17.7.1 Overview
17.7.2 Types
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Quanterix (U.S.)
17.8.1 Overview
17.8.2 Types
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Neurosteer Inc. (U.S.)
17.9.1 Overview
17.9.2 Types
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 R1 RCM Inc., (U.S)
17.9.1 Overview
17.9.2 Types
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
